Drug
Upifitamab Rilsodotin
Upifitamab Rilsodotin: highest development phase Phase 1/2, developed by Mersana Therapeutics. 3 trial records tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Mersana Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| upifitamab rilsodotin NCT03319628 | Phase 1/2 | Platinum Resistant Ovarian Cancer |
| upifitamab rilsodotin NCT06517433 | Phase 1 | Platinum Resistant Ovarian Cancer |
| upifitamab rilsodotin NCT06517485 | Phase 1 | Platinum Resistant Ovarian Cancer |
Latest
No recent events.
Follow Upifitamab Rilsodotin on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.